ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Update and Appendix 4C - quarterly
|
|
hamman
|
36 |
13K |
8 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
36
|
13K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Update and Appendix 4C - quarterly
|
|
hamman
|
36 |
13K |
10 |
01/05/22 |
01/05/22 |
ASX - By Stock
|
36
|
13K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Update and Appendix 4C - quarterly
|
|
hamman
|
36 |
13K |
8 |
01/05/22 |
01/05/22 |
ASX - By Stock
|
36
|
13K
|
8
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
5 |
16/04/22 |
16/04/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Fast Track
|
|
hamman
|
17 |
8.4K |
1 |
13/04/22 |
13/04/22 |
ASX - By Stock
|
17
|
8.4K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Fast Track
|
|
hamman
|
17 |
8.4K |
4 |
12/04/22 |
12/04/22 |
ASX - By Stock
|
17
|
8.4K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Clarification of recent analyst report on Patent Protection
|
|
hamman
|
59 |
26K |
0 |
12/04/22 |
12/04/22 |
ASX - By Stock
|
59
|
26K
|
0
|
|
ASX - By Stock
|
ZIP |
Re:
Daily Price Movement / General Discussion
|
|
hamman
|
46K |
11M |
2 |
11/04/22 |
11/04/22 |
ASX - By Stock
|
46K
|
11M
|
2
|
|
ASX - By Stock
|
ZIP |
Re:
Ann: Zip A$400m Snr CNote offering to accelerate global expansion
|
|
hamman
|
416 |
159K |
5 |
11/04/22 |
11/04/22 |
ASX - By Stock
|
416
|
159K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
An IL-8 Investigation
|
|
hamman
|
9 |
3.7K |
0 |
10/04/22 |
10/04/22 |
ASX - By Stock
|
9
|
3.7K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
10 |
05/04/22 |
05/04/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
10
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
18 |
05/04/22 |
05/04/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
18
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
1 |
05/04/22 |
05/04/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
1 |
29/03/22 |
29/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
hamman
|
4.2K |
3.8M |
20 |
22/03/22 |
22/03/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
20
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
hamman
|
4.2K |
3.8M |
3 |
21/03/22 |
21/03/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Chart
|
|
hamman
|
4.2K |
3.8M |
1 |
18/03/22 |
18/03/22 |
ASX - By Stock
|
4.2K
|
3.8M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Breakthrough arthritis treatments will be available in five years
|
|
hamman
|
23 |
12K |
1 |
14/03/22 |
14/03/22 |
ASX - By Stock
|
23
|
12K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Breakthrough arthritis treatments will be available in five years
|
|
hamman
|
23 |
12K |
2 |
13/03/22 |
13/03/22 |
ASX - By Stock
|
23
|
12K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Breakthrough arthritis treatments will be available in five years
|
|
hamman
|
23 |
12K |
26 |
12/03/22 |
12/03/22 |
ASX - By Stock
|
23
|
12K
|
26
|
|
ASX - By Stock
|
PAR |
Re:
Breakthrough arthritis treatments will be available in five years
|
|
hamman
|
23 |
12K |
5 |
12/03/22 |
12/03/22 |
ASX - By Stock
|
23
|
12K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
1 |
11/03/22 |
11/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
7 |
10/03/22 |
10/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
7
|
|
ASX - By Stock
|
PAR |
Re:
4 months since Phase 3 Green light
|
|
hamman
|
20 |
5.8K |
1 |
08/03/22 |
08/03/22 |
ASX - By Stock
|
20
|
5.8K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
0 |
08/03/22 |
08/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
4 |
08/03/22 |
08/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
4
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
0 |
08/03/22 |
08/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
1 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
1 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
0 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
0 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
0 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
0 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
PATENT REJECTED BUT PAR SILENT
|
|
hamman
|
12 |
6.4K |
1 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
12
|
6.4K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
PATENT REJECTED BUT PAR SILENT
|
|
hamman
|
12 |
6.4K |
2 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
12
|
6.4K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
0 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
1 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
1 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
0 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
0 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
3 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
3
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
1 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
hamman
|
4.1K |
1.9M |
2 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
1 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
4 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
1 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
2 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
30K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
hamman
|
87 |
30K |
12 |
06/03/22 |
06/03/22 |
ASX - By Stock
|
87
|
30K
|
12
|
|
ASX - By Stock
|
AVH |
Re:
Ann: AVITA (AVH) Announces RECELL Receives Japan PMDA Approval
|
|
hamman
|
70 |
21K |
1 |
05/03/22 |
05/03/22 |
ASX - By Stock
|
70
|
21K
|
1
|
|
ASX - By Stock
|
AVH |
Re:
Ann: AVITA Medical signs agreement with Premier Inc
|
|
hamman
|
16 |
4.8K |
3 |
03/03/22 |
03/03/22 |
ASX - By Stock
|
16
|
4.8K
|
3
|
|